Close Menu

NEW YORK (GenomeWeb) – Pharmacogenetics firm Geneticure last week began selling a test for personalizing treatments for high blood pressure via a consumer-facing online model.

However, the company is also pursuing a prospective, randomized controlled trial to demonstrate the safety and efficacy of its test compared to the standard methods of prescribing blood pressure medications. Geneticure plans to submit data from this study to the US Food and Drug Administration for regulatory approval of its test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.